IL278366A - - Google Patents
Info
- Publication number
- IL278366A IL278366A IL27836620A IL27836620A IL278366A IL 278366 A IL278366 A IL 278366A IL 27836620 A IL27836620 A IL 27836620A IL 27836620 A IL27836620 A IL 27836620A IL 278366 A IL278366 A IL 278366A
- Authority
- IL
- Israel
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018085217 | 2018-04-29 | ||
| CN2018107134 | 2018-09-21 | ||
| PCT/CN2019/085001 WO2019210828A1 (en) | 2018-04-29 | 2019-04-29 | Bcl-2 INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL278366A true IL278366A (enExample) | 2020-12-31 |
| IL278366B1 IL278366B1 (en) | 2025-05-01 |
| IL278366B2 IL278366B2 (en) | 2025-09-01 |
Family
ID=68386968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL278366A IL278366B2 (en) | 2018-04-29 | 2019-04-29 | BCL-2 inhibitors |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11420968B2 (enExample) |
| EP (2) | EP4545515A1 (enExample) |
| JP (4) | JP2021521138A (enExample) |
| KR (1) | KR102738032B1 (enExample) |
| CN (3) | CN112437772B (enExample) |
| AU (1) | AU2019264475C1 (enExample) |
| BR (1) | BR112020022092A2 (enExample) |
| CA (1) | CA3098348A1 (enExample) |
| DK (1) | DK3788042T3 (enExample) |
| ES (1) | ES3018793T3 (enExample) |
| FI (1) | FI3788042T3 (enExample) |
| HR (1) | HRP20250392T1 (enExample) |
| HU (1) | HUE071493T2 (enExample) |
| IL (1) | IL278366B2 (enExample) |
| LT (1) | LT3788042T (enExample) |
| MX (2) | MX2020011495A (enExample) |
| PL (1) | PL3788042T3 (enExample) |
| PT (1) | PT3788042T (enExample) |
| SG (1) | SG11202009933WA (enExample) |
| SI (1) | SI3788042T1 (enExample) |
| TW (1) | TWI855062B (enExample) |
| WO (1) | WO2019210828A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110177788B (zh) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | 作为bcl-2选择性凋亡诱导剂的化合物 |
| SI3612531T1 (sl) | 2017-04-18 | 2022-11-30 | Shanghai Fochon Pharmaceutical Co., Ltd. | Sredstva, ki sprožajo apoptozo |
| IL316472A (en) | 2018-01-10 | 2024-12-01 | Recurium Ip Holdings Llc | Benzamide compounds |
| CN112437772B (zh) * | 2018-04-29 | 2023-11-21 | 百济神州有限公司 | Bcl-2抑制剂 |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021083135A1 (en) * | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
| KR20220100992A (ko) | 2019-12-06 | 2022-07-18 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 투여 |
| BR112022012283A2 (pt) | 2019-12-20 | 2022-08-30 | Recurium Ip Holdings Llc | Combinações |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| CN116969937B (zh) | 2020-04-15 | 2026-03-24 | 百济神州(苏州)生物科技有限公司 | Bcl-2抑制剂 |
| MX2022014007A (es) * | 2020-05-08 | 2023-02-09 | Fochon Pharmaceuticals Ltd | Compuestos como inhibidores de bcl-2. |
| WO2022089463A1 (zh) * | 2020-10-28 | 2022-05-05 | 杭州和正医药有限公司 | Bcl-2蛋白凋亡诱导剂及应用 |
| BR112023017371A2 (pt) * | 2021-03-19 | 2023-10-03 | Eil Therapeutics Inc | Compostos que têm ((3-nitrofenil)sulfonil)acetamida como inibidores de bcl-2 |
| US20240239792A1 (en) * | 2021-04-13 | 2024-07-18 | Appicine Therapeutics (Hk) Limited | Modulators of bcl-2 or bcl-2/bcl-xl and uses thereof |
| MX2023014275A (es) * | 2021-06-02 | 2024-03-06 | Beigene Switzerland Gmbh | Métodos de tratamiento de la malignidad de células b utilizando un inhibidor de bcl-2. |
| CN115490708B (zh) * | 2021-06-18 | 2025-01-24 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| MX2024002465A (es) * | 2021-08-31 | 2024-04-29 | Beigene Ltd | Formas solidas de inhibidores de bcl-2, metodo de preparacion y sus usos. |
| WO2023078398A1 (en) * | 2021-11-05 | 2023-05-11 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| JP2024540590A (ja) * | 2021-11-20 | 2024-10-31 | フォチョン・バイオサイエンシーズ・リミテッド | Ｂｃｌ－２阻害剤としての化合物 |
| JP7765790B2 (ja) * | 2021-12-06 | 2025-11-07 | 杭州和正医薬有限公司 | 抗アポトーシスタンパク質ｂｃｌ－２阻害剤、医薬組成物及びその使用 |
| TW202400163A (zh) | 2022-05-12 | 2024-01-01 | 英屬開曼群島商百濟神州有限公司 | 使用ｂｃｌ－２抑制劑治療髓性惡性腫瘤之方法 |
| WO2023231777A1 (en) * | 2022-06-01 | 2023-12-07 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| KR20250079128A (ko) * | 2022-07-21 | 2025-06-04 | 베이진 스위찰랜드 게엠베하 | Bcl-2 저해제를 사용한 다발성 골수종의 치료 방법 |
| WO2024140678A1 (en) * | 2022-12-27 | 2024-07-04 | Beigene (Suzhou) Co., Ltd. | A ketal protected intermediate for sonrotoclax and preparation method thereof |
| WO2024140692A1 (en) * | 2022-12-27 | 2024-07-04 | Beigene (Suzhou) Co., Ltd. | Salts and solid forms of sonrotoclax intermediate |
| WO2024140690A1 (en) * | 2022-12-27 | 2024-07-04 | Beigene (Suzhou) Co., Ltd. | Intermediates of sonrotoclax and the method of preparing the same |
| TW202604488A (zh) | 2024-06-26 | 2026-02-01 | 瑞士商百濟神州Ｉ有限責任公司 | 包含索托克拉固體分散體之醫藥調配物及其製備方法 |
| WO2026019442A1 (en) * | 2024-07-14 | 2026-01-22 | Eil Therapeutics, Inc. | Compounds having (3-nitrophenyl)acetamide as bcl-2 inhibitors |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020055631A1 (en) | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| BRPI0514504A (pt) | 2004-08-20 | 2008-06-10 | Univ Michigan | pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| EP1888543B1 (en) | 2005-05-24 | 2012-08-01 | Abbott Laboratories | Apoptosis promoters |
| MX2009002422A (es) | 2006-09-05 | 2009-03-20 | Abbott Lab | Inhibidores bcl para tratar exceso de plaquetas. |
| WO2009036051A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors containing a zinc binding moiety |
| US8501992B2 (en) | 2008-06-09 | 2013-08-06 | Bristol-Myers Squibb Company | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| NZ614305A (en) | 2008-12-05 | 2015-03-27 | Abbvie Inc | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| CN102307862A (zh) | 2008-12-08 | 2012-01-04 | 贝林格尔.英格海姆国际有限公司 | 用于治疗癌症的化合物 |
| NZ616828A (en) | 2009-01-19 | 2015-03-27 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| RU2538965C2 (ru) | 2009-01-19 | 2015-01-10 | Эббви Инк. | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
| ES2546294T7 (es) * | 2009-05-26 | 2024-06-06 | Abbvie Ireland Unlimited Co | Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| BR112012005343A2 (pt) | 2009-09-10 | 2016-03-22 | Novartis Ag | sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer |
| AU2011229862B2 (en) | 2010-03-25 | 2014-07-24 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| KR20180059560A (ko) | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
| IT1403156B1 (it) | 2010-12-01 | 2013-10-04 | Università Degli Studi Di Torino | Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi. |
| KR101762724B1 (ko) * | 2011-01-25 | 2017-07-28 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법 |
| CN103732589B (zh) | 2011-05-25 | 2016-03-30 | 百时美施贵宝公司 | 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺 |
| WO2013053045A1 (en) | 2011-10-12 | 2013-04-18 | Beta Pharma Canada Inc. | Heterocyclic molecules as apoptosis inducers |
| EA201491265A1 (ru) | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию |
| AU2012355623A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| CA2859873A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| AU2012355624A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| AU2012355613A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| WO2013185202A1 (en) | 2012-06-14 | 2013-12-19 | Beta Pharma Canada Inc | Apoptosis inducers |
| EP2945940B1 (en) | 2013-01-16 | 2020-07-15 | The Regents of The University of Michigan | Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| EP3481397A1 (en) | 2016-07-06 | 2019-05-15 | Concert Pharmaceuticals Inc. | Deuterated venetoclax |
| KR102376764B1 (ko) | 2016-08-05 | 2022-03-18 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 |
| CN109641897B (zh) | 2016-09-01 | 2021-12-07 | 北京赛林泰医药技术有限公司 | Bcl-2选择性抑制剂及其制备和用途 |
| CN106565706B (zh) | 2016-10-27 | 2018-05-01 | 广东东阳光药业有限公司 | 一种磺酰胺衍生物及其在药学中的应用 |
| CN106749233B (zh) | 2016-11-24 | 2020-04-21 | 中山大学 | 一类磺酰胺衍生物及其应用 |
| CN110177788B (zh) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | 作为bcl-2选择性凋亡诱导剂的化合物 |
| SI3612531T1 (sl) | 2017-04-18 | 2022-11-30 | Shanghai Fochon Pharmaceutical Co., Ltd. | Sredstva, ki sprožajo apoptozo |
| MX2020002032A (es) | 2017-08-23 | 2020-09-17 | Guangzhou Lupeng Pharmaceutical Company Ltd | Inhibidores de bcl-2. |
| CN112437772B (zh) | 2018-04-29 | 2023-11-21 | 百济神州有限公司 | Bcl-2抑制剂 |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
-
2019
- 2019-04-29 CN CN201980029015.1A patent/CN112437772B/zh active Active
- 2019-04-29 BR BR112020022092-2A patent/BR112020022092A2/pt active Search and Examination
- 2019-04-29 US US17/050,581 patent/US11420968B2/en active Active
- 2019-04-29 PT PT197970528T patent/PT3788042T/pt unknown
- 2019-04-29 CN CN202311185016.XA patent/CN117430601A/zh active Pending
- 2019-04-29 IL IL278366A patent/IL278366B2/en unknown
- 2019-04-29 LT LTEPPCT/CN2019/085001T patent/LT3788042T/lt unknown
- 2019-04-29 KR KR1020207033817A patent/KR102738032B1/ko active Active
- 2019-04-29 EP EP25150254.8A patent/EP4545515A1/en active Pending
- 2019-04-29 HR HRP20250392TT patent/HRP20250392T1/hr unknown
- 2019-04-29 PL PL19797052.8T patent/PL3788042T3/pl unknown
- 2019-04-29 EP EP19797052.8A patent/EP3788042B1/en active Active
- 2019-04-29 MX MX2020011495A patent/MX2020011495A/es unknown
- 2019-04-29 SG SG11202009933WA patent/SG11202009933WA/en unknown
- 2019-04-29 HU HUE19797052A patent/HUE071493T2/hu unknown
- 2019-04-29 WO PCT/CN2019/085001 patent/WO2019210828A1/en not_active Ceased
- 2019-04-29 CA CA3098348A patent/CA3098348A1/en active Pending
- 2019-04-29 JP JP2020555218A patent/JP2021521138A/ja not_active Withdrawn
- 2019-04-29 SI SI201930922T patent/SI3788042T1/sl unknown
- 2019-04-29 AU AU2019264475A patent/AU2019264475C1/en active Active
- 2019-04-29 FI FIEP19797052.8T patent/FI3788042T3/fi active
- 2019-04-29 ES ES19797052T patent/ES3018793T3/es active Active
- 2019-04-29 DK DK19797052.8T patent/DK3788042T3/da active
- 2019-04-29 CN CN202311486964.7A patent/CN117683029A/zh active Pending
-
2020
- 2020-04-28 TW TW109114185A patent/TWI855062B/zh active
- 2020-10-29 MX MX2023001689A patent/MX2023001689A/es unknown
-
2022
- 2022-05-23 US US17/750,821 patent/US12077536B2/en active Active
-
2024
- 2024-06-11 JP JP2024094048A patent/JP7540113B1/ja active Active
- 2024-06-17 US US18/745,423 patent/US20240376104A1/en active Pending
- 2024-08-14 JP JP2024135320A patent/JP7688210B2/ja active Active
-
2025
- 2025-05-22 JP JP2025085498A patent/JP2025119001A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021000792B8 (enExample) | ||
| AT524874A5 (enExample) | ||
| AT524834A2 (enExample) | ||
| AU2018438767B1 (enExample) | ||
| AT521543A3 (enExample) | ||
| AT524266A2 (enExample) | ||
| BR102019026286B1 (pt) | Método e aparelho para o avanço de produtos a serem moldados | |
| BR102019025884B1 (pt) | Sistema de segurança aprimorado para máquinas de operação de autopropulsão | |
| BR102019023514B1 (pt) | Método para determinar a massa de ar preso em cada cilindro de um motor a combustão interna | |
| BR112020016338B1 (pt) | Dispositivo para tratamento de tecido corporal | |
| BR112021001434B1 (pt) | Aço com alto teor de manganês e método de produção do mesmo | |
| BR112021001374B1 (pt) | Composição farmacêutica para o tratamento da hipertensão e seu uso | |
| BR112021001186B1 (pt) | Aparelho para o tratamento de celulite para tratar expressões de celulite na pele de um paciente associadas a um local de tratamento de septos | |
| BR112020023795B1 (pt) | Composição de recheio para um produto de chocolate à base de gordura, e seus métodos de produção | |
| BR112021000922B1 (pt) | Tela de filtro, e, método para purificar água de alimentação | |
| BR112020026077B1 (pt) | Recipiente com estrutura encaixável | |
| BR112020026721B1 (pt) | Aparelho de moldagem para modar uma folha de um material contendo alcaloides | |
| BR102019012845B1 (pt) | Montagens de guia de entrada de piso de compartimento de carga retráteis para carregamentos paletizados em aeronaves de carga e aeronave e carga | |
| BR112020024987B1 (pt) | Método, montagem e sistema para prover uma estrutura de base, método industrial, e, braço mecânico | |
| BR112020023823B1 (pt) | Distribuidor | |
| BR112020022482B1 (pt) | Composição, anticorpo anti-cd24, anticorpo biespecífico e receptor de antígeno quimérico | |
| BR112020022658B1 (pt) | Método para estimar um nível de pressão sonora, sistema de fone de ouvido, fone de ouvido e uso do fone de ouvido | |
| BR112020022516B1 (pt) | Processo para degomagem enzimática de óleo | |
| BR112020021042B1 (pt) | Compostos de carboxamidas bicíclicas, composição farmacêutica e uso das mesmas | |
| BR112020020812B1 (pt) | Composições de tratamento de superfícies duras, seu uso, método para proporcionar ação antimicrobiana residual e substrato relacionado |